Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vacc 4x

Drug Profile

Vacc 4x

Alternative Names: HIV vaccine Vacc-4x; Vacc-4x; ™Kick, Kill and Boost strategy - Bionor Holding

Latest Information Update: 13 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bionor Immuno
  • Developer Bionor Holding; Bionor Pharma; Celgene Corporation; Eurocine; Oslo University Hospital; University of Bergen; University of Oslo
  • Class AIDS vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Immunostimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II HIV-1 infections

Most Recent Events

  • 06 Aug 2019 Bionor Holding completes the phase II trial in HIV-infections in Denmark (EudraCT2015-003186-28)
  • 31 Jul 2019 Vacc-4x is still in phase II development for HIV-1 infections (Combination therapy) in Denmark (Intradermal) (EudraCT2015-003186-28)
  • 31 Jul 2019 No development reported - Phase-II for HIV-1 infections (Combination therapy) in Germany (Intradermal) (NCT01704781)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top